NEW YORK (GenomeWeb) – Canadian life sciences firm DiagnoCure announced today that its board has approved a plan to voluntarily dissolve the company and liquidate its assets.
"The board of directors of DiagnoCure has determined that the liquidation and dissolution is advisable and in the best interest of the corporation and its shareholders," DiagnoCure Chairman Jacques Simoneau said in a statement.
A special meeting will be held on May 19 to submit the plan to shareholders for their approval. If the plan is approved, PricewaterhouseCoopers will be appointed liquidator. DiagnoCure also said it will submit an application to have its shares delisted from the Toronto Stock Exchange.
In December, DiagnoCure sold its PCA3 prostate cancer biomarker and related assets to Hologic subsidiary Gen-Probe. Simoneau said that the company had been in discussions to sell other assets related to its multi-marker prostate cancer test and its Previstage GCC colorectal cancer test, but these failed to result in formal offers.
"Given the limited financial resources remaining after the distribution to the shareholders of substantially all the proceeds from the PCA3 asset sale transaction, the corporation has decided to initiate a liquidation and dissolution process," Simoneau added.
Earlier this year, DiagnoCure reported finishing 2015 with C$1.1 million in cash and short-term investments amid swelling losses and dropping revenues.